Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback